Gene · 607
Papers1,232
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,232
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
ZD-4009, a novel B-cell lymphoma 9 inhibitor, is associated with ameliorated pulmonary fibrosis and reduced hypoxia-inducible factor 1α-mediated glycolysis and transforming growth factor-β/SMAD signaling. | Mol Pharmacol | 2026 | 42721930 | PubTator, text mining | PubMed |
| BCL9 inhibition promotes fibroblast lipogenesis by regulating macrophage-fibroblast interactions to attenuate pulmonary fibrosis. | Signal Transduct Target Ther | 2026 | 42543261 | PubTator, text mining | PubMed |
| [Clinical analysis of 9 children of B-cell acute lymphoblastic leukemia with MEF2D gene rearrangement]. | Zhonghua Er Ke Za Zhi | 2026 | 42527140 | PubTator, text mining | PubMed |
| Targeting BCL9/BCL9L enhances CD4+ T cell-mediated Th1 antitumor immunity through activation of STAT1/STAT4 signaling. | Acta Pharmacol Sin | 2026 | 42366227 | PubTator, text mining | PubMed |
| ZW4864-mediated inhibition of the β-catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer. | Mol Oncol | 2026 | 42316797 | PubTator, text mining | PubMed |
| Determination of copy number variations and affected gene networks in breast cancer. | Biomed Rep | 2026 | 42221547 | PubTator, text mining | PubMed |
| Disruption of BCL9-β-catenin interaction by de novo designed miniproteins inhibits oncogenic signaling. | Int J Biol Macromol | 2026 | 42190771 | PubTator, text mining | PubMed |
| Probiotic-derived EPS-ZnO nanoparticles: therapeutic potential in colorectal cancer gene regulation. | Cancer Cell Int | 2026 | 42092948 | PubTator, text mining | PubMed |
| Erratum for the Research Article "Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling". | Sci Transl Med | 2026 | 42054497 | PubTator, text mining | PubMed |
| Therapeutic Activities of Multipotent Stromal Cells for Islet Regeneration. | Cells | 2026 | 41892279 | PubTator, text mining | PubMed |
| The clinical characteristics and prognosis analysis of acute B-cell lymphoblastic leukemia with MEF2D fusions. | Ann Hematol | 2026 | 41870600 | PubTator, text mining | PubMed |
| Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances. | Mol Biomed | 2026 | 41826571 | PubTator, text mining | PubMed |
| Genomic Landscape of Poorly Differentiated Gastric Carcinoma: An AACR GENIE® Project. | Life (Basel) | 2026 | 41752847 | PubTator, text mining | PubMed |
| The Association of Environmental Variables with Intelligence and Well-Being in Copy Number Variation (CNV) Carriers. | Res Sq | 2026 | 41727601 | PubTator, text mining | PubMed |
| Identifying genes and pathways in familial lymphoid cancers using whole exome sequencing. | Leuk Lymphoma | 2026 | 41652927 | PubTator, text mining | PubMed |
| Wnt-associated DKK3 in keratinocytes mediates radiation-induced hyperplasia, dermatitis and skin fibrosis. | Signal Transduct Target Ther | 2026 | 41629266 | PubTator, text mining | PubMed |
| The GC-derived exosomal LncRNA DARS-AS1 activates Wnt/β-catenin pathway to drive angiogenesis by regulating miR-605-5p/BCL9. | J Cancer Res Clin Oncol | 2026 | 41563498 | PubTator, text mining | PubMed |
| BCL9 as a Key Player in Wnt/β-catenin Signaling: Implications for Osteogenesis, Tissue Repair, and Oncology. | Appl Biochem Biotechnol | 2026 | 41222773 | PubTator, text mining | PubMed |
| Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation. | Nat Commun | 2025 | 41249197 | PubTator, text mining | PubMed |
| Disruption of β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction Using Heterogeneous Peptidomimetic Foldamers. | J Am Chem Soc | 2025 | 41178037 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/607/papers